The Phase 1/2 trial will be conducted initially in normal healthy volunteers, and, then, in patients with PH1. Initiation of this trial is based on encouraging pre-clinical data
ImmuPharma is pleased to confirm that the first European site in Bordeaux, France is open and the patient recruitment process in Europe has now commenced. This follows on
NEB’s rapid business growth and a desire for real-time business intelligence led to the decision to migrate NEB’s instances of SAP ERP to the SAP HANA platform. After
Submission of the MAA for Xilonix is necessary for the Company to gain approval to sell the drug in European Union member nations. The Company, which only recently
Proceeds will be used to advance the company’s immunotherapy programs. These programs include its lead drug candidate, an anti-CCR4 monoclonal antibody for the treatment of cancer, which is
The trial was a pivotal Phase 2/3 study designed to evaluate KEYTRUDA compared to chemotherapy based on prospective measurement of PD-L1 expression in previously treated patients with advanced
8,736 men with metastatic prostate cancer were analysed by Susan Halabi Ph.D. and colleagues from leading US and international cancer research centres. Patients where cancer has spread to
The FDA’s Fast Track programme is designed to expedite the development and review of drugs to treat serious conditions and fill an unmet medical need. MEDI8852 is currently
"CDI results from damage to the microbiome, and patients experience further collateral damage through the use of broad spectrum antibiotics to treat CDI, leaving them vulnerable to recurrent
The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE). "We are advancing XmAb5871 in IgG4-RD
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.